Betterlife director Beaudry resigns; arranges debt deal

Executive Summary

• Betterlife Pharma Inc. converted accrued interest on its convertible debentures into 57,945 common shares and issued an equal number of share purchase warrants at $0.10 exercise price, expiring September 27 2026.
• The conversion represents a total principal amount of approximately $5,795.
• Board member Andre Beaudry resigned; the company will announce new corporate adviser(s) in the coming weeks.

Key Details

• Conversion Mechanics: Accrued interest on convertible debentures totaling $5,795 was converted into 57,945 common shares.
• Warrant Issuance: Simultaneously, 57,945 share purchase warrants were issued, each allowing the holder to purchase one common share at an exercise price of $0.10 per share.
• Warrant Terms: All warrants expire on September 27 2026.
• Board Change: Andre Beaudry resigned from Betterlife Pharma’s board of directors effective immediately.
• Future Advisory Appointment: The company indicated that new corporate adviser(s) will be appointed and announced in the near term.

Notable Quotes

(No direct quotes were provided in the release.)